Oscar Health Inc. Reports Q2 2025 Revenue Surge to $2.86B, Net Loss of $228.4M, EPS Drops to $(0.89)

Reuters
08/06
Oscar Health Inc. Reports <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Revenue Surge to $2.86B, Net Loss of $228.4M, EPS Drops to $(0.89)

Oscar Health Inc. has released its financial results for the second quarter of 2025, reporting a total revenue of $2.86 billion, a significant increase from $2.22 billion in the same period of 2024. However, the company posted a net loss attributable to Oscar Health, Inc. of $228.4 million, compared to a net income of $56.2 million in the second quarter of 2024. The medical loss ratio rose to 91.1% from 79.0% in the previous year, while the SG&A expense ratio decreased to 18.7% from 19.6%. Oscar Health reported a loss from operations amounting to $230.5 million, compared to a gain from operations of $67.8 million in the second quarter of 2024. The company attributes the decrease to an increase in average market morbidity, resulting in a higher risk adjustment transfer accrual. Membership numbers for Oscar Health increased, with total membership reaching 2,027,148 as of June 30, 2025, up from 1,580,725 in the same period of the previous year. The Adjusted EBITDA showed a loss of $199.4 million for the second quarter of 2025, a downturn from a positive Adjusted EBITDA of $104.1 million in the second quarter of 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oscar Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250806320230) on August 06, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10